The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06601075

Enrollment

Registered

2024-09-19

Start date

2025-02-01

Completion date

2029-03-31

Last updated

2025-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Colorectal Cancer

Keywords

68Ga-FAPI PET/CT, diagnosis, advanced colorectal cancer, efficacy evaluation

Brief summary

This study aims to investigate the value of 18F-FDG and 68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of advanced colorectal cancer (peritoneal metastasis with/without other metastases)

Detailed description

The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 18F-FDG and 68Ga-FAPI PET/CT at baseline and after 3 months of conversion therapy. The imaging response measurements will be compared with the histopathological or clinical assessment results as gold standard.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Histologically confirmed colorectal cancer, clinical or other imaging suspicion of peritoneal metastasis with or without other distant metastases. 2. Patients voluntarily enrolled in this study by signing an informed consent form 3. Age ≥ 18 years 4. Expected life expectancy ≥ 3 months 5. Adequate organ and bone marrow function 6. Willingness to adhere to the study protocol and follow-up programme

Exclusion criteria

1. Pregnant or breastfeeding women. 2. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix 3. Severe mental disease, uncontrolled epilepsy, or central nervous system disease 4. Subjects with current concurrent interstitial pneumonitis or interstitial lung disease, or subjects with previous interstitial pneumonitis or interstitial lung disease requiring hormonal therapy, or subjects with other conditions that may interfere with the judgement and management of immune-related pulmonary toxicity, e.g., pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pneumoconiosis, Drug-associated pneumonia, idiopathic pneumonia, active pneumonia, or severe pulmonary impairment on CT; and active tuberculosis

Design outcomes

Primary

Measure	Time frame	Description
Diagnostic accuracy	Baseline and up to 3 months	18F-FDG and 68Ga-FAPI PET/CT was used to diagnose the lesions of the patients, and the diagnostic performance of PET/CT was evaluated by comparing the diagnostic results with the pathological results/clinical evaluation results.
Standardized uptake value(SUV)	Baseline and up to 3 months	SUV of 68Ga-FAPI and 18F-FDG uptake on PET/CT images for tumor lesions
Target-to-background ratio(TBR)	Baseline and up to 3 months	68Ga-FAPI and 18F-FDG uptake ratio of tumor lesions to mediastinum and liver blood pool on PET/CT images.

Secondary

Measure	Time frame	Description
Progress free survival	3 years	Progress free survival
Overall survival	3 years	Overall survival

Countries

China

Contacts

Primary ContactJiajia Hu

jiajiahu@shsmu.edu.cn13524945287

Outcome results